大型队列研究中儿童和青少年镰状细胞病患者镰状细胞视网膜病变的调查
该研究基于镰状细胞研究与干预项目队列中2010年10月至2022年9月单中心10-18岁患者的2237次眼科检查,发现接受羟基脲治疗者发生SCR的可能性降低29%(30% vs 42%,P=0.0028),接受慢性输血者降低68%(17% vs 40%,P<0.001),作者支持广泛使用羟基脲、慢性输血或两者。
要点
- 接受羟基脲的351例中107例(30%)有SCR,未接受者279例中118例(42%)有SCR(P=0.0028)。
- 接受慢性输血的121例中20例(17%)有视网膜病变,未接受者509例中205例(40%)有视网膜病变(P<0.001)。
- 作者认为这些治疗与较少的患者出现SCR相关,支持广泛使用羟基脲、慢性输血或两者。
核心结论
- 来自最大的儿童和青少年镰状细胞病队列之一的数据支持广泛使用羟基脲、慢性输血或两者,这些治疗与较少的患者出现SCR相关。
研究设计与样本
- 利用大型纵向队列研究,纳入镰状细胞研究与干预项目队列中2010年10月至2022年9月单中心初次眼科检查时年龄10-18岁参与者的所有眼科检查,排除未行散瞳眼底检查者。
- 血红蛋白SC病患者从10岁开始每年进行眼科评估,其他镰状细胞基因型每两年一次,两名眼科医生审阅全部2237次眼科检查结果。
主要发现
- 接受羟基脲治疗的儿童和青少年镰状细胞病患者发生SCR的可能性降低29%,接受者351例中107例(30%)有SCR,未接受者279例中118例(42%)有SCR(P=0.0028)。
- 接受慢性输血的患者发生SCR的可能性降低68%,接受者121例中20例(17%)有视网膜病变,未接受者509例中205例(40%)有视网膜病变(P<0.001)。
关键数值与推荐
- SCR患病率:羟基脲组30%(107/351) vs 非羟基脲组42%(118/279),P=0.0028。
- SCR患病率:慢性输血组17%(20/121) vs 非慢性输血组40%(205/509),P<0.001。
临床怎么用
- 作者认为数据支持广泛使用羟基脲、慢性输血或两者,这些治疗与较少的患者出现SCR相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sickle cell disease results in vaso-occlusion and hemolysis, leading to ophthalmic and systemic complications. In the eye, these processes initiate retinal ischemia and neovascularization resulting in sickle cell retinopathy (SCR). Hydroxyurea therapy increases fetal hemoglobin (reducing ischemia), and chronic blood transfusions (CTXN) reduce strokes in children with abnormally high intracranial vessel velocities. It is not known if these treatments reduce retinopathy. Our hypothesis is that hydroxyurea and CTXN lower the risk of the development and slow the progression of retinopathy. DESIGN: Using a large longitudinal cohort study, we determined the prevalence of SCR among pediatric and adolescent patients with sickle cell disease and the effects of disease-modifying therapy on reducing the prevalence and severity of sickle cell retinopathy. PARTICIPANTS: We included all eye examinations of participants (age 10-18 at time of initial eye exam) at a single site from the Sickle Cell Research and Intervention Program cohort between October 2010 and September 2022. Patients without a dilated eye exam were excluded. METHODS: At 10 years of age, yearly ophthalmologic assessments began for patients with hemoglobin SC disease and every other year for other sickle cell genotypes. Two ophthalmologists reviewed all 2237 eye examination results. MAIN OUTCOME MEASURES: We obtained patient age, sex, sickle genotype, treatment received for sickle cell retinopathy, duration of exposure to sickle cell disease-modifying therapy, and hematologic indices (fetal hemoglobin and hemoglobin concentration) and abstracted data regarding SCR, severity grading, and treatment. RESULTS: We observed that pediatric and adolescent patients with sickle cell disease receiving hydroxyurea therapy were 29% less likely to demonstrate SCR. Of those receiving hydroxyurea, 107 of 351 patients (30%) had SCR as compared with the 118 of 279 patients (42%) not receiving hydroxyurea (P = 0.0028). Patients receiving CTXN were 68% less likely to develop SCR. Of those, 20 of 121 patients (17%) had retinopathy as compared with the 205 of 509 patients (40%) not receiving CTXN (P < 0.001). CONCLUSIONS: Our data from one of the largest cohorts of pediatric and adolescent patients with sickle cell disease support widespread use of hydroxyurea, CTXN, or both. We found that these therapies are associated with a smaller number of patients demonstrating SCR. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Smith BD, Hankins JS, Kang G, et al. Investigation of Sickle Cell Retinopathy in Pediatric and Adolescent Patients Enrolled in a Large Cohort Study. Ophthalmology. 2025. PMID: 40188852. doi:10.1016/j.ophtha.2025.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。